OR WAIT 15 SECS
© 2020 MJH Life Sciences and Drug Topics. All rights reserved.
© 2020 MJH Life Sciences™ and Drug Topics. All rights reserved.
September 03, 2020
Study suggests higher hospitalization rate for some skin diseases.
May 26, 2020
Dupilumab (Dupixent, Sanofi and Regeneron) is the first biologic medicine approved for treatment of moderate-to-severe atopic dermatitis.
May 08, 2020
Apremilast (Otezla, Amgen) significantly improved psoriasis symptoms compared with a placebo in adults with mild-to-moderate disease.
March 24, 2020
Crisaborole ointment, 2% (Eucrisa, Pfizer) has been approved for use in pediatric patients with atopic dermatitis as young as 3 months of age.
March 23, 2020
Phase 3 clinical data demonstrate abrocitinib’s efficacy and safety in treating moderate-to-severe atopic dermatitis in adults.
February 04, 2020
Baricitinib (Olumiant, Eli Lilly and Incyte) demonstrated positive results in the BREEZE-AD5 study of patients with atopic dermatitis.
January 28, 2020
If approved, dupilumab (Dupixent, Regeneron and Sanofi) would be indicated for use as an add-on maintenance treatment for children ages 6 to 11 years with moderate-to-severe atopic dermatitis.
January 17, 2020
Pharmacists can play an integral role in managing patients with psoriasis through medication therapies and lifestyle modifications.
October 21, 2019
Available for prescribing starting January 2020
October 18, 2019
Originally approved in 1995 for use in adults only.